The estimated Net Worth of Ross B Levin is at least $299 Tisíc dollars as of 7 March 2019. Mr. Levin owns over 6,826 units of Stereotaxis stock worth over $58,819 and over the last 7 years he sold STXS stock worth over $0. In addition, he makes $240,300 as Independent Director at Stereotaxis.
Ross has made over 1 trades of the Stereotaxis stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 6,826 units of STXS stock worth $26,212 on 7 March 2019.
The largest trade he's ever made was buying 6,826 units of Stereotaxis stock on 7 March 2019 worth over $26,212. On average, Ross trades about 379 units every 0 days since 2017. As of 7 March 2019 he still owns at least 26,981 units of Stereotaxis stock.
You can see the complete history of Mr. Levin stock trades at the bottom of the page.
Ross B. Levin serves as Independent Director of the Company. Mr. Levin is the Director of Research for Arbiter Partners Capital Management LLC and a principal in the firm. Mr. Levin serves on the board of directors for Capital Senior Living Corporation and is a former board member of Mood Media Corporation, American Community Properties Trust and Presidential Life Corporation. Mr. Levin is also Vice Chairman of the Board of Directors of the Cerebral Palsy Association of New York State. Mr. Levin is a member of the New York Society of Securities Analysts and a CFA charter holder. Mr. Levin holds a Bachelor of Science degree in Management with a concentration in Finance from the A.B. Freeman School of Business at Tulane University and has completed the Investment Decisions and Behavioral Finance program at the John F. Kennedy School of Government at Harvard University. Mr. Levin’s securities industry experience and experience with other publicly traded companies permits him to offer valuable insight into corporate governance, audit, and risk and liability issues.
As the Independent Director of Stereotaxis, the total compensation of Ross Levin at Stereotaxis is $240,300. There are no executives at Stereotaxis getting paid more.
Ross Levin is 36, he's been the Independent Director of Stereotaxis since 2018. There are 6 older and 3 younger executives at Stereotaxis. The oldest executive at Stereotaxis, Inc. is Robert Messey, 74, who is the Independent Director.
Ross's mailing address filed with the SEC is C/O STEREOTAXIS, INC., 710 NORTH TUCKER BOULEVARD; SUITE 110, ST. LOUIS,, MO, 63101.
Over the last 6 years, insiders at Stereotaxis have traded over $16,447,723 worth of Stereotaxis stock and bought 502,585 units worth $872,120 . The most active insiders traders include Joe E Kiani, Paul J Isaac a Myriam Curet. On average, Stereotaxis executives and independent directors trade stock every 39 days with the average trade being worth of $124,591. The most recent stock trade was executed by Paul J Isaac on 28 May 2024, trading 1,254 units of STXS stock currently worth $2,358.
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
Stereotaxis executives and other stock owners filed with the SEC include: